Literature DB >> 9152490

Albumin priming does not prolong hemofilter life.

J H Reeves1, P F Seal, A L Voss, C O'Connor.   

Abstract

The hypothesis was tested that prepriming a hemofilter and lines with heparinized human albumin (NSA) instead of heparinized saline (NS) increases filter survival time. In a university affiliated intensive care unit, all patients were eligible who required continuous venovenous hemodiafiltration and who did not have pre-existing coagulopathy or contraindications to heparin. New hemofilters were randomized to priming with 2 liters NS or 1 liter NS followed by 500ml NSA. The prime was recirculated for at least 30 minutes before connection to the patient. Anticoagulation was tightly controlled, aiming for a patient activated partial thromboplastin time (APTT) of 60 seconds. Survival analysis was used to compare filter life. Elective discontinuation (e.g., for surgery) were treated as censored data. A total of 91 hemofilters were used in 40 patients during 9 months: 45 randomized to NS, and 46 to NSA. Of these, 57 hemofilters were used until spontaneous failure, 28 NS and 29 NSA; 34 hemofilters were electively discontinued, 17 in each group. Anticoagulation was identical in both groups; the mean APTT value (+/- SE) was 58.2 seconds (+/- 3.1) for NS and 58.0 seconds (+/- 2.8) for NSA (p > 0.9 unpaired t-test). Platelet counts were very similar at 170 x 10(9) (+/- 21.8) for NS and 181 x 10(9) (+/- 23.7) for NSA (p = 0.74 unpaired t-test). There was no significant difference in the filter life between the two groups. For NS, median filter life was 37.8 hours (range 0.6-120); for NSA, median filter life was 45.4 hours (range 2.5-109; p = 0.998 log rank). The power to detect a 50% improvement in filter life was > 90%. Based on this data, the use of albumin priming as an aid to increased hemofilter life can not be recommended.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9152490

Source DB:  PubMed          Journal:  ASAIO J        ISSN: 1058-2916            Impact factor:   2.872


  4 in total

Review 1.  Anticoagulation strategies in continuous renal replacement therapy: can the choice be evidence based?

Authors:  H M Oudemans-van Straaten; J P J Wester; A C J M de Pont; M R C Schetz
Journal:  Intensive Care Med       Date:  2006-02-02       Impact factor: 17.440

2.  Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.

Authors:  Hiraku Tsujimoto; Yasushi Tsujimoto; Yukihiko Nakata; Tomoko Fujii; Sei Takahashi; Mai Akazawa; Yuki Kataoka
Journal:  Cochrane Database Syst Rev       Date:  2020-03-13

Review 3.  Non anti-coagulant factors associated with filter life in continuous renal replacement therapy (CRRT): a systematic review and meta-analysis.

Authors:  Matthew Brain; Elizabeth Winson; Owen Roodenburg; John McNeil
Journal:  BMC Nephrol       Date:  2017-02-20       Impact factor: 2.388

4.  Evaluation of Different Dialyzers and the Impact of Predialysis Albumin Priming in Intermittent Hemodialysis With Reduced Anticoagulation.

Authors:  Floris Vanommeslaeghe; Filip De Somer; Iván Josipovic; Matthieu Boone; Wim Van Biesen; Sunny Eloot
Journal:  Kidney Int Rep       Date:  2019-07-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.